Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized, Non-Inferiority Trial of AAR/AAR+HAR Versus AAR+TAR+FET in Type A Aortic Intramural Hematoma

NCT07272655 is registered in ClinicalTrials.gov with Second Hospital of Jilin University as lead sponsor.

NCT NCT07272655
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07272655 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized, Non-Inferiority Trial of AAR/AAR+HAR Versus AAR+TAR+FET in Type A Aortic Intramural Hematoma
Lead sponsor
Second Hospital of Jilin University
Phase
Not applicable
Overall status
Not yet recruiting
Start date
October 1, 2026
Completion date
October 30, 2027
Enrollment
400 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

aortic intramural hematoma